Scynexis (SCYX) Income from Discontinued Operations (2014 - 2015)
Scynexis' (SCYX) quarterly Income from Discontinued Operations came in at -$826000.0 in Q3 2015, down 308.59% on a YoY basis from $396000.0 in Q3 2014, and up 72.51% quarter-over-quarter from -$3.0 million in Q2 2015.
Powered by 
Analysis
Scynexis (SCYX) Income from Discontinued Operations (2014 - 2015) Analysis & Trends
Scynexis (SCYX) has reported Income from Discontinued Operations for 2 consecutive years, with -$826000.0 the latest figure, recorded in Q3 2015.
- For the quarter ending Q3 2015, Income from Discontinued Operations fell 308.59% year-over-year to -$826000.0; the trailing twelve-month figure through Jun 2016 stood at -$826000.0 (up 70.06% YoY), and the FY2015 full-year result was -$4.3 million, down 413.0% from the prior year.
- Income from Discontinued Operations grew to -$826000.0 in Q3 2015 per SCYX's latest filing, from -$3.0 million in the prior quarter.
- Across five years, Income from Discontinued Operations topped out at $562000.0 in Q2 2014 and bottomed at -$3.0 million in Q2 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2015 | -826,000.00 |
| Jun 30, 2015 | -3.01 Mn |
| Mar 31, 2015 | -453,000.00 |
| Dec 31, 2014 | 303,000.00 |
| Sep 30, 2014 | 396,000.00 |
| Jun 30, 2014 | 562,000.00 |